Importantly, we unveiled that, in addition to activating the β-Catenin signaling via classical enzyme activity approach, CAPN2 could also promote Hedgehog signaling activation through the non-enzyme approach, synergistically promoting the occurrence of Lenvatinib resistance in HCC. Here, CAPN2 is linked to hepatocellular carcinoma.